Transcriptomic predictors of survival for palbociclib + endocrine therapy vs. capecitabine in aromatase inhibitor-resistant breast cancer from GEICAM/2013-02 PEARL

We examined transcriptomic tumor features associated with survival from GEICAM/2013-02 PEARL, a phase III trial of palbociclib + ET vs. capecitabine in aromatase inhibitor-resistant HR+/HER2- MBC. PAM50 intrinsic subtype predicted PFS differences between palbociclib + ET and capecitabine, and lower B-cell-associated gene expression predicted longer OS with palbociclib + ET vs. capecitabine. These features may help identify HR+/HER2- tumors resistant to further ET-based treatment with CDK4/6 inhibitors.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001015613	Formalin fixed, paraffin-embedded human breast cancer tumor samples had RNA extracted using the Thermo Scientific KingFisher Flex instrument and the Applied Biosystems MagMAX FFPE DNA/RNA Ultra Kit; Total RNA libraries were created using the Bravo Automated Liquid-Handling Platform and the TruSeq Stranded Total RNA Library Prep Gold Kit; libraries were sequenced on the Illumina NovaSeq 6000 machine using a 2x50 bp paired-end configuration to target a read depth of 120 million clusters per library.	Illumina NovaSeq 6000	328

Publications	Citations
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial. Agrawal YN, Fernández-Martínez A, Gil-Gil M, Zielinski C, Ruiz-Borrego M, Ciruelos EM, Muñoz M, Margelí M, Bermejo B, Antón A, Kahan Z, Csöszi T, Alonso-Romero JL, García-Saenz JÁ, Sánchez-Rovira P, Álvarez E, Chacón JI, González-Santiago S, Rodríguez CA, Servitja S, Pfefferle AD, Herranz J, Liu Y, Carey LA, Romero-Camarero I, Caballero R, Guerrero-Zotano Á, Perou CM, Martín M. JCO Precis Oncol 9: 2025 e2400937	0

Publications

Citations

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.
Agrawal YN, Fernández-Martínez A, Gil-Gil M, Zielinski C, Ruiz-Borrego M, Ciruelos EM, Muñoz M, Margelí M, Bermejo B, Antón A, Kahan Z, Csöszi T, Alonso-Romero JL, García-Saenz JÁ, Sánchez-Rovira P, Álvarez E, Chacón JI, González-Santiago S, Rodríguez CA, Servitja S, Pfefferle AD, Herranz J, Liu Y, Carey LA, Romero-Camarero I, Caballero R, Guerrero-Zotano Á, Perou CM, Martín M. JCO Precis Oncol 9: 2025 e2400937